Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,624 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,624 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $46.66, for a total value of $169,095.84. Following the sale, the director now owns 356,022 shares in the company, valued at approximately $16,611,986.52. The trade was a 1.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pro-Dex Trading Down 3.7 %

PDEX traded down $1.74 during midday trading on Tuesday, reaching $45.00. 15,511 shares of the company’s stock traded hands, compared to its average volume of 31,039. The firm has a fifty day moving average of $48.04 and a two-hundred day moving average of $32.32. The stock has a market capitalization of $146.66 million, a price-to-earnings ratio of 29.22 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PDEX. Dimensional Fund Advisors LP raised its position in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares during the last quarter. Geode Capital Management LLC raised its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the last quarter. Bard Associates Inc. raised its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. FMR LLC raised its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after acquiring an additional 900 shares in the last quarter. Institutional investors own 15.28% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PDEX. Ascendiant Capital Markets upped their price objective on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.